Lixte Biotechnology Holdings, Inc.(LIXT)Earnings, Financials & Key Ratios
LIXT•NASDAQ
$4.40
$25M mkt cap·Price updated May 6, 2026
AboutLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.Show more
- Revenue$0
- EBITDA-$4M+29.6%
- Net Income-$4M+29.5%
- EPS (Diluted)-1.59+40.2%
- ROE-148.73%-33.9%
LIXT Key Insights
Lixte Biotechnology Holdings, Inc. (LIXT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 17.4% in last year
- ✗Expensive at 12.0x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LIXT Price & Volume
Lixte Biotechnology Holdings, Inc. (LIXT) stock price & volume — 10-year historical chart
Loading chart...
LIXT Growth Metrics
Lixte Biotechnology Holdings, Inc. (LIXT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-3.33%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM33.71%
Return on Capital
10 Years-279.49%
5 Years-122.2%
3 Years-128.71%
Last Year-148.19%
LIXT Peer Comparison
Lixte Biotechnology Holdings, Inc. (LIXT) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ONCY | 99M | 0.92 | -3.05 | -7.55% | 0.18 | |||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 CRIS | 81.2M | 0.62 | -1.06 | -13.43% | -80.29% | -138.81% | 0.30 |
Compare LIXT vs Peers
Lixte Biotechnology Holdings, Inc. (LIXT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LIXT Income Statement
Lixte Biotechnology Holdings, Inc. (LIXT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -100% | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 2.13M | 1.81M | 2.14M | 2.49M | 3.27M | 6.72M | 6.31M | 5.09M | 3.57M | 3.9M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 833.78K | 1.34M | 2.1M | 1.67M | 2.04M | 4.98M | 4.96M | 4.19M | 2.85M | 3.66M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.3M | 467.26K | 40.7K | 820.91K | 1.22M | 1.74M | 1.35M | 898.1K | 726.23K | 237.63K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.13M▲ 0% | -1.81M▲ 15.2% | -2.14M▼ 18.1% | -2.49M▼ 16.5% | -3.27M▼ 31.2% | -6.72M▼ 105.7% | -6.31M▲ 6.1% | -5.09M▲ 19.3% | -3.57M▲ 29.8% | -3.9M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 19.32% | 15.23% | -18.14% | -16.46% | -31.18% | -105.74% | 6.09% | 19.35% | 29.81% | - |
| EBITDA | 0 | 0 | 0 | -2.44M | 0 | -6.72M | -6.3M | -5.07M | -3.57M | -2.8M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 100% | - | - | - | 100% | - | 6.21% | 19.56% | 29.61% | 5.13% |
| D&A (Non-Cash Add-back) | 2.13M | 1.81M | 2.14M | 0 | 3.27M | 0 | 0 | 0 | 0 | 1.32M |
| EBIT | -2.13M | -1.81M | -2.13M | -2.44M | -3.27M | -6.72M | -6.3M | -5.07M | -3.57M | -4.12M |
| Net Interest Income | 0 | 0 | 0 | 49.72K | 1.56K | -6.79K | 2.32K | 1.25K | 7.05K | -4.08K |
| Interest Income | 183 | 1.38K | 4.92K | 49.72K | 5.23K | 626 | 11.2K | 1.25K | 7.05K | 5.75K |
| Interest Expense | 183 | 1.38K | 4.92K | 0 | 3.67K | 7.41K | 8.88K | 0 | 0 | 9.83K |
| Other Income/Expense | 183 | 1.38K | 4.92K | 49.72K | 1.56K | -7.95K | -1.05K | 3.21K | -13.18K | -237.09K |
| Pretax Income | -2.13M▲ 0% | -1.81M▲ 15.3% | -2.13M▼ 18.0% | -2.44M▼ 14.4% | -3.26M▼ 33.8% | -6.73M▼ 106.1% | -6.31M▲ 6.2% | -5.09M▲ 19.4% | -3.59M▲ 29.5% | -4.13M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -2.13K | -1.81K | -9.85K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.1% | 0.1% | 0.46% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.13M▲ 0% | -1.81M▲ 15.3% | -2.13M▼ 18.0% | -2.44M▼ 14.4% | -3.26M▼ 33.8% | -6.73M▼ 106.1% | -6.31M▲ 6.2% | -5.09M▲ 19.4% | -3.59M▲ 29.5% | -4.13M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 25.15% | 15.29% | -17.96% | -14.4% | -33.79% | -106.08% | 6.18% | 19.41% | 29.51% | -3.33% |
| Net Income (Continuing) | -2.13M | -1.81M | -2.13M | -2.44M | -3.26M | -6.73M | -6.31M | -5.09M | -3.59M | -4.13M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.68▲ 0% | -1.94▲ 27.6% | -2.18▼ 12.4% | -2.20▼ 0.9% | -2.89▼ 31.4% | -5.00▼ 73.0% | -4.00▲ 20.0% | -2.66▲ 33.5% | -1.59▲ 40.2% | -0.67▲ 0% |
| EPS Growth % | 26.78% | 27.61% | -12.37% | -0.92% | -31.36% | -73.01% | 20% | 33.5% | 40.23% | 33.71% |
| EPS (Basic) | -2.68 | -1.94 | -2.18 | -2.20 | -2.89 | -5.00 | -4.00 | -2.66 | -1.59 | - |
| Diluted Shares Outstanding | 797.93K | 930.29K | 979.93K | 1.12M | 1.13M | 1.35M | 1.58M | 1.92M | 2.25M | 6.17M |
| Basic Shares Outstanding | 797K | 930K | 979.93K | 1.12M | 1.13M | 1.35M | 1.58M | 1.91M | 2.25M | 6.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LIXT Balance Sheet
Lixte Biotechnology Holdings, Inc. (LIXT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 433.41K | 1.37M | 4.33M | 2.67M | 5.23M | 5.09M | 5.56M | 4.31M | 1.04M | 5.43M |
| Cash & Short-Term Investments | 199.93K | 1.31M | 4.27M | 2.6M | 5.07M | 4.82M | 5.35M | 4.2M | 1.04M | 5.34M |
| Cash Only | 199.93K | 1.31M | 4.27M | 2.6M | 5.07M | 4.82M | 5.35M | 4.2M | 1.04M | 2.89M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.45M |
| Accounts Receivable | 0 | 0 | 0 | 14.37K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 62.32K | 61.43K | 24.29K | 15K | 150.24K | 0 | 0 | -106.55K | 0 |
| Total Non-Current Assets | 0 | 0 | 2.29K | 0 | 76.9K | 0 | 0 | 0 | 106.55K | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 2.29K | 0 | 76.9K | 0 | 0 | 0 | 106.55K | 198.83K |
| Total Assets | 433.41K▲ 0% | 1.37M▲ 215.7% | 4.34M▲ 217.0% | 2.67M▼ 38.4% | 5.23M▲ 95.7% | 5.09M▼ 2.6% | 5.56M▲ 9.2% | 4.31M▼ 22.5% | 1.15M▼ 73.4% | 5.43M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -27.52% | 215.65% | 217% | -38.39% | 95.67% | -2.59% | 9.18% | -22.52% | -73.41% | 33.73% |
| Total Current Liabilities | 218.65K | 373.02K | 210.91K | 237.9K | 216.52K | 302.93K | 395.76K | 313.86K | 318.28K | 521.42K |
| Accounts Payable | 159.59K | 312.03K | 195.21K | 143.55K | 190.29K | 193.47K | 183.75K | 120.51K | 83.21K | 235.9K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 59.06K | 60.99K | 15.7K | 94.35K | 15.77K | 0 | 165.02K | 157.1K | 235.08K | 969K |
| Other Current Liabilities | 0 | 60.99K | 0 | 0 | 0 | 76.96K | 0 | 0 | 0 | 50.37K |
| Current Ratio | 1.98x | 3.67x | 20.55x | 11.23x | 24.15x | 16.81x | 14.05x | 13.73x | 3.26x | 3.26x |
| Quick Ratio | 1.98x | 3.67x | 20.55x | 11.23x | 24.15x | 16.81x | 14.05x | 13.73x | 3.26x | 3.26x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 218.65K | 373.02K | 210.91K | 237.9K | 216.52K | 302.93K | 395.76K | 313.86K | 318.28K | 521.42K |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -199.93K | -1.31M | -4.27M | -2.6M | -5.07M | -4.82M | -5.35M | -4.2M | -1.04M | -2.89M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.03x |
| Interest Coverage | -11666.20x | -1316.21x | -434.30x | - | -889.07x | -906.45x | -711.15x | - | - | -419.37x |
| Total Equity | 214.76K▲ 0% | 995.04K▲ 363.3% | 4.13M▲ 314.6% | 2.43M▼ 41.0% | 5.01M▲ 105.9% | 4.79M▼ 4.4% | 5.17M▲ 7.8% | 3.99M▼ 22.7% | 827.22K▼ 79.3% | 4.91M▲ 0% |
| Equity Growth % | -31.24% | 363.33% | 314.64% | -41% | 105.9% | -4.42% | 7.83% | -22.66% | -79.29% | 46.15% |
| Book Value per Share | 0.27 | 1.07 | 4.21 | 2.18 | 4.44 | 3.56 | 3.26 | 2.08 | 0.37 | 0.80 |
| Total Shareholders' Equity | 214.76K | 995.04K | 4.13M | 2.43M | 5.01M | 4.79M | 5.17M | 3.99M | 827.22K | 4.91M |
| Common Stock | 4.79K | 5.8K | 6.7K | 6.7K | 1.24K | 1.37K | 166 | 225 | 225 | 570 |
| Retained Earnings | -20.71M | -22.52M | -24.65M | -27.09M | -30.35M | -37.08M | -43.39M | -48.48M | -52.07M | -55.53M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LIXT Cash Flow Statement
Lixte Biotechnology Holdings, Inc. (LIXT) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.68M | -1.41M | -1.51M | -1.67M | -2.13M | -4.14M | -4.61M | -4.29M | -3.16M | -3.16M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 23.09% | 15.81% | -7% | -10.79% | -27.31% | -94.37% | -11.32% | 6.91% | 26.29% | 105.31% |
| Net Income | -2.13M | -1.81M | -2.13M | -2.44M | -3.26M | -6.73M | -6.31M | -5.09M | -3.59M | -4.13M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 287.16K | 70.69K | 785.61K | 748.65K | 1.25M | 2.6M | 1.55M | 773.2K | 418.42K | 1.27M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 87.16K | -81.74K | 902.43K | 0 | 0 | 0 | 0 | 0 | 0 | 182.89K |
| Working Capital Changes | 170.13K | 325.54K | -163.52K | 17.54K | -117.88K | -13.44K | 154.76K | 20.56K | 3.01K | 52K |
| Change in Receivables | 200K | 0 | 0 | -14.37K | 14.37K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 35.12K | 0 | 0 | 14.37K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 519 | 152.44K | -116.82K | -51.66K | 46.74K | 35.67K | 2.32K | 0 | -73.55K | 95.66K |
| Cash from Investing | 104.09K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.64M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 104 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.75M | 2.52M | 4.48M | 0 | 4.6M | 3.9M | 5.14M | 3.14M | 0 | 6.47M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1.75M | 2.5M | 4.5M | 0 | 4.6M | 3.69M | 5.14M | 3.14M | 0 | 6.47M |
| Dividends Paid | -2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 18K | -21.7K | 0 | 0 | 207.63K | 0 | 6.32K | 0 | 0 |
| Net Change in Cash | 174.65K▲ 0% | 1.11M▲ 533.2% | 2.97M▲ 168.3% | -1.67M▼ 156.4% | 2.47M▲ 247.6% | -245.52K▼ 109.9% | 529.65K▲ 315.7% | -1.15M▼ 317.1% | -3.16M▼ 175.2% | 1.25M▲ 0% |
| Free Cash Flow | -1.68M▲ 0% | -1.41M▲ 15.8% | -1.51M▼ 7.0% | -1.67M▼ 10.8% | -2.13M▼ 27.3% | -4.14M▼ 94.4% | -4.61M▼ 11.3% | -4.29M▲ 6.9% | -3.16M▲ 26.3% | -2.58M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 23.09% | 15.81% | -7% | -10.79% | -27.31% | -94.37% | -11.32% | 6.91% | 26.29% | 25.57% |
| FCF per Share | -2.10 | -1.52 | -1.54 | -1.50 | -1.89 | -3.07 | -2.92 | -2.24 | -1.41 | -1.41 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.78x | 0.71x | 0.69x | 0.65x | 0.62x | 0.73x | 0.84x | 0.88x | 0.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 3.67K | 7.41K | 0 | 16.23K | 0 | 4.43K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LIXT Key Ratios
Lixte Biotechnology Holdings, Inc. (LIXT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -810% | -298.96% | -83.31% | -74.4% | -87.69% | -137.28% | -126.81% | -111.07% | -148.73% | -219% |
| Return on Invested Capital (ROIC) | -1060.8% | - | - | - | - | - | - | - | - | -865.06% |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Interest Coverage | -11666.20x | -1316.21x | -434.30x | - | -889.07x | -906.45x | -711.15x | - | - | -419.37x |
| FCF Conversion | 0.79x | 0.78x | 0.71x | 0.69x | 0.65x | 0.62x | 0.73x | 0.84x | 0.88x | 0.62x |
| Revenue Growth | -100% | - | - | - | - | - | - | - | - | - |
LIXT Frequently Asked Questions
Lixte Biotechnology Holdings, Inc. (LIXT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lixte Biotechnology Holdings, Inc. (LIXT) grew revenue by 0.0% over the past year. Growth has been modest.
Lixte Biotechnology Holdings, Inc. (LIXT) reported a net loss of $4.1M for fiscal year 2024.
Dividend & Returns
Lixte Biotechnology Holdings, Inc. (LIXT) has a return on equity (ROE) of -148.7%. Negative ROE indicates the company is unprofitable.
Lixte Biotechnology Holdings, Inc. (LIXT) had negative free cash flow of $2.6M in fiscal year 2024, likely due to heavy capital investments.
Explore More LIXT
Lixte Biotechnology Holdings, Inc. (LIXT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates